{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:48:22Z","timestamp":1792608502539,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009098","name":"Japanese Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.resinv.2024.10.004","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T01:34:55Z","timestamp":1728956095000},"page":"1168-1175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-4519","authenticated-orcid":false,"given":"Hiroshi","family":"Ohnishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7100-6077","authenticated-orcid":false,"given":"Takuya","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1715-9670","authenticated-orcid":false,"given":"Masamitsu","family":"Eitoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.10.004_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1183\/09059180.00002610","article-title":"Impact of exacerbations on COPD","volume":"19","author":"Anzueto","year":"2010","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2024.10.004_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1183\/16000617.00002215","article-title":"Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis","volume":"24","author":"Cazzola","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2024.10.004_bib4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1080\/15412555.2017.1347918","article-title":"Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis","volume":"14","author":"Cazzola","year":"2017","journal-title":"COPD"},{"key":"10.1016\/j.resinv.2024.10.004_bib5","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2147\/COPD.S140603","article-title":"Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis","volume":"12","author":"Zeng","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2024.10.004_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: a European respiratory society\/American thoracic society guideline","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.10.004_bib7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.hrtlng.2016.12.004","article-title":"The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: a meta-analysis and systematic review","volume":"46","author":"Fowdar","year":"2017","journal-title":"Heart Lung"},{"key":"10.1016\/j.resinv.2024.10.004_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.pupt.2017.11.009","article-title":"Impact of erdosteine on chronic bronchitis and COPD: a meta-analysis","volume":"48","author":"Cazzola","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.resinv.2024.10.004_bib9","doi-asserted-by":"crossref","unstructured":"Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic\/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res 20197;20:104.doi: 10.1186\/s12931-019-1078-y.","DOI":"10.1186\/s12931-019-1078-y"},{"key":"10.1016\/j.resinv.2024.10.004_bib10","article-title":"Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease","volume":"5","author":"Poole","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.resinv.2024.10.004_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17534666231158563","article-title":"The efficacy of N-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis","volume":"17","author":"Huang","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.resinv.2024.10.004_bib12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.chest.2023.08.014","article-title":"Canadian thoracic society guideline on pharmacotherapy in patients with stable COPD","volume":"164","author":"Bourbeau","year":"2023","journal-title":"Chest"},{"issue":"20","key":"10.1016\/j.resinv.2024.10.004_bib13","article-title":"Pharmacologic and nonpharmacologic therapies in adult patients with exacerbation of COPD: a systematic review [internet]","volume":"19","author":"Dobler","year":"2019","journal-title":"Rockville (MD): Agency for Healthcare Research and Quality (US)"},{"key":"10.1016\/j.resinv.2024.10.004_bib14","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"10.1016\/j.resinv.2024.10.004_bib15","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/bmj.2.5213.1665","article-title":"Standardized questionnaires on respiratory symptoms","volume":"2","year":"1960","journal-title":"Br Med J"},{"key":"10.1016\/j.resinv.2024.10.004_bib16","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.resinv.2024.10.004_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.resinv.2024.10.004_bib18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.resinv.2024.10.004_bib19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/thx.40.11.832","article-title":"Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction","volume":"40","author":"McGavin","year":"1985","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2024.10.004_bib20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000029447","article-title":"N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD","volume":"66","author":"Pela","year":"1999","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2024.10.004_bib21","first-page":"12","article-title":"Effect of oral N-acetylcysteine in COPD - a randomised controlled trial","volume":"14","author":"Bachh","year":"2007","journal-title":"JK Pract"},{"key":"10.1016\/j.resinv.2024.10.004_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1378\/chest.09-0421","article-title":"Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study","volume":"136","author":"Stav","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.10.004_bib23","first-page":"48","article-title":"Study of malondialdehyde as an indicator of oxidative stress and its modulation by N-acetylcysteine in chronic obstructive pulmonary disease","volume":"5","author":"Patil","year":"2011","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.resinv.2024.10.004_bib24","first-page":"799","article-title":"High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial","volume":"11","author":"Johnson","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2024.10.004_bib25","first-page":"6122","article-title":"The effects of N-acetylcysteine on the Th1\/Th2 ratio in elderly patients with chronic obstructive pulmonary disease","volume":"12","author":"Wang","year":"2019","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.resinv.2024.10.004_bib26","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2024.10.004_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1378\/chest.12-2357","article-title":"High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study","volume":"144","author":"Tse","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.10.004_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1378\/chest.13-2784","article-title":"Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD","volume":"146","author":"Tse","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.10.004_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","article-title":"Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial","volume":"2","author":"Zheng","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.10.004_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.rmed.2018.12.014","article-title":"Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post-hoc analysis of the PANTHEON study","volume":"147","author":"Papi","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.10.004_bib31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000196540","article-title":"Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial","volume":"63","author":"Allegra","year":"1996","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2024.10.004_bib32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1532-5415.2005.00592_9.x","article-title":"Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease","volume":"54","author":"Yasuda","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.resinv.2024.10.004_bib33","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/j.1532-5415.2007.01373.x","article-title":"Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease","volume":"55","author":"Tatsumi","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.resinv.2024.10.004_bib34","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study","volume":"371","author":"Zheng","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2024.10.004_bib35","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00711-2017","article-title":"Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study","volume":"50","author":"Dal Negro","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.10.004_bib36","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.2147\/COPD.S221852","article-title":"Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation","volume":"14","author":"Calverley","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2024.10.004_bib37","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2147\/COPD.S369804","article-title":"The effect of maintenance treatment with erdosteine on exacerbation treatment and health status in patients with COPD: a post-hoc analysis of the RESTORE dataset","volume":"17","author":"Calverley","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2024.10.004_bib38","first-page":"143","article-title":"The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study","volume":"30","author":"Moretti","year":"2004","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.resinv.2024.10.004_bib39","first-page":"9","article-title":"The effect of a mucoactive drug (ambroxol Hydrochloride) on health-related quality of life in patients with chronic obstructive pulmonary disease","volume":"43","author":"Ueda","year":"2004","journal-title":"Wakayama Med Rep"},{"key":"10.1016\/j.resinv.2024.10.004_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pupt.2003.08.004","article-title":"Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial)","volume":"17","author":"Malerba","year":"2004","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.resinv.2024.10.004_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1185\/03007997809111916","article-title":"Clinical therapeutic evaluation of methylcysteine hydrochloride in patients with chronic obstructive bronchitis: a balanced double-blind trial with placebo control","volume":"5","author":"Aylward","year":"1978","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.resinv.2024.10.004_bib42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.02.00063702","article-title":"Interpreting thresholds for a clinically significant change in health status in asthma and COPD","volume":"19","author":"Jones","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.10.004_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1440-1843.2004.00611.x","article-title":"Clinical phenotypes of COPD: results of a Japanese epidemiological survey","volume":"9","author":"Tatsumi","year":"2004","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2024.10.004_bib44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1465-9921-11-122","article-title":"Characterisation of COPD heterogeneity in the ECLIPSE cohort","volume":"11","author":"Agusti","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2024.10.004_bib45","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1378\/chest.10-2948","article-title":"The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study","volume":"140","author":"Kim","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.10.004_bib46","series-title":"The JRS guideline for the management of chronic obstructive pulmonary disease 2022","first-page":"216","year":"2022"},{"key":"10.1016\/j.resinv.2024.10.004_bib47","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0954-6111(05)80337-3","article-title":"Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis","volume":"88","author":"Hansen","year":"1994","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.10.004_bib48","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.rmed.2008.11.003","article-title":"Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis","volume":"103","author":"Schermer","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.10.004_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1378\/chest.97.1.75","article-title":"The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis","volume":"97","author":"Petty","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.10.004_bib50","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2147\/COPD.S103105","article-title":"Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study","volume":"11","author":"Fukuchi","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2024.10.004_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1465-9921-10-69","article-title":"Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial","volume":"10","author":"Worth","year":"2009","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2024.10.004_bib52","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/crj.13690","article-title":"Efficacy of treatment with N-acetylcysteine inhalation for AECOPD: a propensity-score-matched cohort study","volume":"17","author":"Chen","year":"2023","journal-title":"Clin RespirJ"},{"key":"10.1016\/j.resinv.2024.10.004_bib53","first-page":"108","article-title":"The efficacy and safety of inhaled acetylcysteine in comparison with oral acetylcysteine in chronic obstructive pulmonary disease: a randomized single-center study","volume":"27","author":"Kuzmenko","year":"2020","journal-title":"Pol Ann Med"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:32:49Z","timestamp":1739345569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524001618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2212534524001618"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.10.004","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}